Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
MENRIUM 5-2 is an oral tablet small molecule approved by Roche in 1966 for an undisclosed indication. The product is approaching loss of exclusivity and represents a legacy therapeutic from the mid-20th century pharmaceutical era.
Product is in end-of-life stage with minimal commercial infrastructure; teams are typically lean and focused on transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked job openings reflect this product's late-lifecycle status and minimal staffing needs. Career opportunities on MENRIUM 5-2 are limited to legacy brand maintenance roles with low visibility and growth potential.
Worked on MENRIUM 5-2 at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.